Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: QVM149

First Posted Date: 2017-04-04

Last Posted Date: 2020-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03100825

Locations: 🇯🇵
Novartis Investigative Site, Toshima ku, Tokyo, Japan

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)
Biological: Placebo Pre-Filled Syringe (PFS)

First Posted Date: 2017-03-30

Last Posted Date: 2022-03-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 246

Registration Number: NCT03096834

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Advanced Metastatic Breast Cancer

Interventions: Drug: ribociclib
Drug: letrozole
Drug: goserelin

First Posted Date: 2017-03-30

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 502

Registration Number: NCT03096847

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

Phase 2

Terminated

Conditions: Post-herpetic Neuralgia

Interventions: Drug: EMA401
Drug: Placebo

First Posted Date: 2017-03-29

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT03094195

Locations: 🇬🇧
Novartis Investigative Site, Liverpool, United Kingdom

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: QAW039
Drug: QAW39A
Drug: QAW39A2107

First Posted Date: 2017-03-23

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03087942

Locations: 🇩🇪
Novartis Investigative Site, Grunstadt, Germany

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: spartalizumab (PDR001)
Drug: regorafenib

First Posted Date: 2017-03-16

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT03081494

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Phase 3

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Ribociclib
Drug: Adjuvant endocrine therapy

First Posted Date: 2017-03-16

Last Posted Date: 2018-03-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03081234

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Adjuvant endocrine therapy
Drug: Placebo

First Posted Date: 2017-03-13

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03078751

Locations: 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸
Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States

and more 30 locations

Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

Completed

Conditions: Alport Nephropathy

First Posted Date: 2017-03-08

Last Posted Date: 2018-11-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03074357

Locations: 🇺🇸
Novartis Investigative Site, Minneapolis, Minnesota, United States

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2

Withdrawn

Conditions: Basal Cell Carcinoma

Interventions: Drug: LDE225B
Drug: Vehicle

First Posted Date: 2017-03-03

Last Posted Date: 2017-05-05

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03070691

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece
🇬🇧
Novartis Investigative site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy